Melanie Szweras, Partner, Bereskin & Parr LLP to Speak at The Knowledge Group’s Biotech and Pharmaceutical Patent Law
The Knowledge Group, the leading producer of regulatory-focused webcasts, has announced today that Melanie Szweras, Partner, Bereskin & Parr LLP will speak at its webcast entitled, “Biotech and Pharmaceutical Patent Law: Cutting-Edge Issues to Watch For.”
- (1888PressRelease) September 15, 2022 - This event is scheduled for September 16, 2022 from 12:00 PM to 1:30 PM ET.
For further details, please visit: https://knowledgewebcasts.com/know-portfolio/biotech-and-pharmaceutical-patent-law-cle/
About Melanie Szweras
Melanie Szweras is a partner with Bereskin & Parr LLP. Melanie’s practice focuses on biotechnology and pharmaceutical patents including drafting and prosecution of such applications; providing validity and freedom to operate opinions as well as patent litigation matters. Melanie also advises on regulatory matters, such as labeling and advertising, for consumer goods and regulated products such as food and drugs.
Melanie is a lecturer for the second-year Intellectual Property Law Course at the Lincoln Alexander School of Law at Ryerson University. She also lectures on aspects of Biotechnology and The Application Process at the University of Toronto’s Patent & Trade Secrets Law course and Osgoode Hall’s LLM Patent Law course.
About Bereskin & Parr LLP
Bereskin & Parr LLP (B&P) is a leading Canadian full-service intellectual property law firm serving clients across all industries around the world. Founded in 1965, the firm has grown to be one of the largest intellectual property (IP) firms in Canada with offices located in major economic and technology centres. The firm is made up of more than 75 lawyers and patent and trademark agents, many of whom are recognized as leading practitioners in their specialized fields. The firm has established a depth of legal talent and systems to service clients in every aspect of patent, trademark and copyright law and IP litigation. The firm and its award-winning professionals are consistently ranked as the benchmark for IP law in Canada.
Event Summary
Several court cases continue to shape the biotech and pharmaceutical patent litigation in the United States and Canada.
In the United States, Amgen Inc. v. Sanofi-Aventis (2021) has revived the discussion on the enablement of genus claims in biotechnology inventions. Moreover, the multiple filings for abbreviated new drug applications (ANDA) also raise concerns, particularly in cases that may provoke multidistrict litigation. These and other developments further expand the patent litigation landscape, introducing new regulations that practitioners must be aware of to avoid legal pitfalls.
In Canada, summary trials are increasingly affecting the way litigation is proceeding. Issues concerning cases that impact the scope of the Notice of Allegation, certificates of supplementary protection, and the Patent Medicines Price Review Board, as well as those relating to claim construction, obviousness, and patentable subject matter, must be considered.
Join a panel of key thought leaders and distinguished professionals organized by The Knowledge Group as they provide a comprehensive discussion of the recent litigation trends in the biotech and pharmaceutical industry. Speakers, among other things, will also offer practical tips and strategies in this ever-changing regulatory landscape.
Key Topics include:
• Recent Litigation Trends and Developments in the Biotech and Pharmaceutical Industry
• Enablement of Genus Claims for Biotechnology Inventions
• Multiple Filing of Abbreviated New Drug Applications (ANDA): Implications
• Recent and Notable Court Cases
• What Lies Ahead
About The Knowledge Group
Founded in November 2006, The Knowledge Group has been at the forefront of providing quality continuing education programs for lawyers, accountants, financial executives, risk and compliance specialists, human resources professionals, technology officers, and business consultants in a wide range of industries.
The Knowledge Group strives to be the best-in-class provider of continuing education by bringing forth relevant content you can’t get anywhere else.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam